eligibility_summary
Eligible: CD20+ follicular lymphoma grade 1–3a, stage II bulky or III/IV, need for treatment, measurable disease on CT/MRI, ECOG 0–2, adequate bone marrow and hepatic function. Exclude: CNS/leptomeningeal lymphoma, transformed high-grade/DLBCL, WM, grade 3b FL, CLL/SLL, prior systemic anti-lymphoma therapy, active infections or hypersensitivity to study drug/excipients. Other protocol criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, randomized trial in untreated follicular lymphoma comparing: 1) Odronextamab (REGN1979) — an anti‑CD20×CD3 bispecific IgG T‑cell–engaging antibody, it links CD20 on malignant B cells to CD3 on T cells, activating cytotoxic T cells to kill CD20+ B cells (induction and maintenance). 2) Standard rituximab-based chemoimmunotherapy with maintenance rituximab: Rituximab — anti‑CD20 monoclonal antibody mediating ADCC, complement activation, and apoptosis, Chemotherapy backbones per investigator: CHOP or CVP [cyclophosphamide (alkylator DNA crosslinker), doxorubicin (anthracycline/topoisomerase II inhibitor, ROS), vincristine (microtubule inhibitor), prednisone/prednisolone (glucocorticoid lympholytic)] or bendamustine (alkylating agent). Targets/pathways: CD20+ follicular B cells, CD3/T‑cell activation, DNA replication/crosslinking, topoisomerase II, microtubules, and glucocorticoid receptor signaling.